Part 21, after stem cell treatment, I don #39;t recommend it, 08June2013
My name is Carole St-Laurent, I am from Rimouski, Quebec, Canada. I have a Spinal Muscular Atrophy from birth, it #39;s in the family of Muscular Dystrophy. I re...
By: Kina Diamond
See the original post:
Part 21, after stem cell treatment, I don't recommend it, 08June2013 - Video
Stem cells treatment for avascular necrosis (AVN) in India
Stem cell treatment treatment of AVN in India can cure early AVN. AVN is a condition that affects young patients. Often the cause is unknown. It invariably p...
By: ALAMPALLAM VENKATACHALAM
Here is the original post:
Stem cells treatment for avascular necrosis (AVN) in India - Video
Released: 6/11/2013 2:00 PM EDT Source Newsroom: Mayo Clinic
June 11, 2013
MULTIMEDIA ALERT: Animation of the surgical procedure as well as audio and video of Drs. Nelson and Burkhart are available for download from the Mayo Clinic News Network.
http://www.mayoclinic.org/news2013-rst/7521.html
Newswise ROCHESTER, Minn. -- Mayo Clinic has announced the first U.S. stem cell clinical trial for pediatric congenital heart disease. The trial aims to determine how stem cells from autologous umbilical cord blood can help children with hypoplastic left heart syndrome (HLHS), a rare defect in which the left side of the heart is critically underdeveloped.
The trial will test the safety and feasibility of delivering a personalized cell-based therapy into the heart of 10 infants affected by HLHS. Today, treatment for babies born with HLHS involves three heart surgeries to redirect blood flow through the heart, or transplantation. The surgeries -- designed to provide adequate blood flow in and out of the heart, allowing the body to receive the oxygen-rich blood it needs -- are typically performed over the first few years of life. For this study, stem cells from newborns with HLHS will be collected from the umbilical cord following birth. The cord blood will be sent to a Mayo Clinic lab for processing, where the stem cells will be separated from the other cells in the blood. The stem cells will then be frozen for preservation. During the babys second surgery for HLHS -- typically performed at 4 to 6 months of age -- the stem cells will be injected into the heart muscle.
We want to see if these stem cells will increase the volume and strength of the heart muscle to give it greater durability and power to pump blood throughout the body, says Harold Burkhart, M.D., a pediatric cardiovascular surgeon with the Mayo Clinic Childrens Center.
About 960 babies are born with hypoplastic left heart syndrome each year in the U.S., the Centers for Disease Control and Prevention estimates. In this syndrome, the left side of the heart cant properly supply blood to the body because the lower left chamber (left ventricle) is too small or, in some cases, may not exist, Dr. Burkhart says. In addition, the valves on the left side of the heart (aortic valve and mitral valve) dont work properly, and the main artery leaving the heart (aorta) is smaller than normal, he says.
The care of these children with HLHS has been continuously improving since the first surgical procedure became available three decades ago, yet cardiac transplantation continues to be the limiting factor for far too many individuals, says Timothy Nelson, M.D., Ph.D., director of the Todd and Karen Wanek Family Program for HLHS in Mayo Clinics Center for Regenerative Medicine. Applying stem cell-based regeneration may offer a viable solution to help these children develop new tissues and grow stronger hearts.
# # # About Mayo Clinic Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit http://www.mayoclinic.com and http://www.mayoclinic.org/news.
See the article here:
Mayo Clinic First in US to Test Stem Cells in Pediatric Congenital Heart Disease Patients
BOCA RATON, FL--(Marketwired - Jun 11, 2013) - At Stem Cell Orthopedics, Medical Director Dr. Joseph Purita and his staff, are focused on utilizing the latest practices in regenerative medicine to offer innovative procedures to patients suffering from a wide range of injuries and degenerative conditions. Specifically, Dr. Purita and the other board-certified orthopedic surgeons at Stem Cell Orthopedics concentrate on the progressive use of platelet rich plasma (PRP) injection and stem cell therapies. Although Purita has already gained increasing recognition for his revolutionary use of regenerative medicine, he is encouraged by the continuing progress found within the medical community.
As such, Dr. Joseph Purita highlights a recent study emerging from scientific researchers at the University of Pennsylvania focused in a new report from Science Daily. The article explains, "Bioengineers are interested in finding innovative ways to grow new cartilage from a patient's own stem cells, and, thanks to a new study from the University of Pennsylvania, such a treatment is a step closer to reality." Directed under the guidance of associated professor Jason Burdick, the research took a closer examination of how stem cells may improve and resolve the natural deterioration of cartilage experienced through aging, or sports injuries.
In the article, Burdick explains, "The broad picture is trying to develop new therapies to replace cartilage tissue, starting with focal defects -- things like sports injuries -- and then hopefully moving toward surface replacement for cartilage degradation that comes with aging. Here, we're trying to figure out the right environment for adult stem cells to produce the best cartilage."
Dr. Joseph Purita responds to the study, "Having successfully treated notable athletes with regenerative medicine procedures -- such as PRP therapy -- I am confident that stem cells will continue to offer more comprehensive benefits over traditional resolutions. While the research continues to develop, it is encouraging that in the near future patients will no longer have to opt for expensive invasive surgery options to repair damaged cartilage, joints, tissue, blood vessels and bone."
While Dr. Joseph Purita is excited by the scientific developments offered by the University of Pennsylvania research, he explains that there are many other benefits that may come with further studies. "While the scientific understanding of stem cells is critical to applying the resource in regenerative medicine, it is important to note that continued research will help ease the public's perception of regenerative medicine. As patients come to understand that the solution can be found in our own bodies, I believe the public will prove more open to these types of innovative therapies," Dr. Joseph Purita concludes.
ABOUT:
Dr. Joseph Purita is the Medical Director Stem Cell Orthopedics, a medical facility based in Boca Raton, Florida that specializes in regenerative medicine treatments. The facility serves a wide range of patients who are experiencing chronic pain as the result of a degenerative disorder or physical injury. This center is equipped with experienced board-certified orthopedic surgeons who understand how to target and treat specific conditions ranging from rheumatoid arthritis to tears in muscle tissue. While founded on a conventional knowledge of traditional orthopedics, this facility is regarded for its progressive use of emerging methodologies, including platelet rich plasma (PRP) injection, stem cell and cytokine therapies.
Excerpt from:
Dr. Joseph Purita Celebrates New Study on Stem Cell Cartilage Formation
MOUNTAIN VIEW, Calif., June 10, 2013 /PRNewswire/ -- SanBio Inc., a California-based regenerative medicine company, announced today that the U.S. Food and Drug Administration has approved their Investigational New Drug application (IND) for the use of SB623, a novel allogeneic stem cell therapy product, in patients suffering from traumatic brain injuries (TBI's). This approval allows the company to proceed with a Phase 1/2a clinical trial testing the safety and feasibility of the therapy. The clinical trial is expected to be carried out at several major hospitals in the United States.
"This is the second clinical program for SanBio," said Keita Mori, SanBio's Chief Executive Officer, "we see this as a clear validation of our development program and a significant broadening of the therapeutic application of our lead product SB623 for the treatment of unaddressed chronic neurological deficits."
"We measure the responses of TBI patients to physical therapy every day. Progress is often painfully slow and incremental," said Dr. Daniel Lu, Principal Investigator, Neuroplasticity and Repair Laboratory and Director, Neuromotor Recovery Research Center, University of California, Los Angeles, "If this new cell therapy approach improves outcomes it could have a dramatic positive effect on many lives."
About Traumatic Brain Injury: According to the Center for Disease Control and Prevention, more the 1.7 million people in the United States sustain a traumatic brain injury each year, resulting in approximately 50,000 deaths and 275,000 hospitalizations. Many of these more severely injured patients suffer permanent disabilities, including loss of motor function and cognitive impairment. Other than physical rehabilitation there is no effective therapy. Direct medical costs and indirect costs such as lost productivity of TBI totaled an estimated $76.5 billion in the United States in 2000.
About SB623: SB623 is a proprietary cell therapy product consisting of cells derived from genetically modified bone marrow stromal cells obtained from healthy adult donors. SB623 is administered adjacent to the damaged area of the brain. SB623 functions by producing factors that aid the regenerative process.
About SanBio: SanBio is a privately held San Francisco Bay Area biotechnology company focused on the discovery and development of new regenerative cell therapy products.
For more information: http://www.san-bio.com
Read the original:
SanBio Announces FDA Clearance for the Initiation of a Phase I/2a Clinical Trial Testing Their Cell Therapy Product ...
CANCER sufferer Kate Blackhurst is recovering at home after undergoing a revolutionary stem cell transplant to try to beat the disease.
The 20-year-old, picturedright, was offered the treatment on the NHS after being struck down with cancer twice in three years.
The latest treatment saw some of Kate's healthy stem cells frozen by experts at The Queen Elizabeth Hospital, in Birmingham.
She then received chemotherapy five times more powerful than a normal dose to try to kill the cancerous cells as the frozen stem cells were put back in her body during almost four weeks of treatment last month.
myprint-247
Print voucher
Our heavyweight cards have FREE UV silk coating, FREE next day delivery & VAT included. Choose from 1000's of pre-designed templates or upload your own artwork. Orders dispatched within 24hrs.
Terms: Visit our site for more products: Business Cards, Compliment Slips, Letterheads, Leaflets, Postcards, Posters & much more. All items are free next day delivery. http://www.myprint-247.co.uk
Contact: 01858 468192
Valid until: Sunday, June 16 2013
Visit link:
The Sentinel commented Staffordshire cancer sufferer undergoes revolutionary treatment
CANCER sufferer Kate Blackhurst is recovering at home after undergoing a revolutionary stem cell transplant to try to beat the disease.
The 20-year-old, picturedright, was offered the treatment on the NHS after being struck down with cancer twice in three years.
The latest treatment saw some of Kate's healthy stem cells frozen by experts at The Queen Elizabeth Hospital, in Birmingham.
She then received chemotherapy five times more powerful than a normal dose to try to kill the cancerous cells as the frozen stem cells were put back in her body during almost four weeks of treatment last month.
myprint-247
Print voucher
Our heavyweight cards have FREE UV silk coating, FREE next day delivery & VAT included. Choose from 1000's of pre-designed templates or upload your own artwork. Orders dispatched within 24hrs.
Terms: Visit our site for more products: Business Cards, Compliment Slips, Letterheads, Leaflets, Postcards, Posters & much more. All items are free next day delivery. http://www.myprint-247.co.uk
Contact: 01858 468192
Valid until: Sunday, June 16 2013
Here is the original post:
'I'LL BEAT THIS CANCER AGAIN'
Washington, June 10 (ANI): Liver transplantation is the mainstay of treatment for patients with end-stage liver disease, but a new research from the Icahn School of Medicine at Mount Sinai has suggested that it may one day become possible to regenerate a liver using cell therapy in patients with liver disease.
Investigators discovered that a human embryonic stem cell can be differentiated into a previously unknown liver progenitor cell, an early offspring of a stem cell, and produce mature and functional liver cells.
"The discovery of the novel progenitor represents a fundamental advance in this field and potentially to the liver regeneration field using cell therapy," said the study's senior author, Valerie Gouon-Evans, PharmD, PhD, Assistant Professor, in the Department of Developmental and Regenerative Biology, Black Family Stem Cell Institute, at the Icahn School of Medicine at Mount Sinai.
"Until now, liver transplantation has been the most successful treatment for people with liver failure, but we have a drastic shortage of organs. This discovery may help circumvent that problem,"
In conjunction with the laboratory of Matthew J. Evans, PhD, from the Department of Microbiology at Icahn School of Medicine at Mount Sinai, investigators demonstrated the functionality of the liver cells generated from the progenitors, as the liver cells can be infected by the hepatitis C virus, a property restricted to liver cells exclusively.
A critical discovery in this research was finding that the novel progenitor has a receptor protein on its cell surface called KDR, or vascular endothelial growth factor receptor 2, which until now, was thought to be restricted to endothelial cells that form vessels, the progenitors for endothelial cells and the progenitors blood cells.
The research team showed that activation of KDR on these novel liver progenitors differentiates them into mature liver cells. Additionally, work in a mouse model revealed similar cells, indicating that the progenitors are conserved from mouse to human, and therefore, they must be "important cells with promising potential for cell therapy in treating liver disease," explained Dr. Gouon-Evans.
Next, the research team will examine specifically whether these liver cells obtained from human embryonic stem cells in a dish help repair injured livers in preclinical animal models of liver disease.
The study was published in the journal Cell Stem Cell. (ANI)
Read the original:
Newly discovered cell shows promise for liver regeneration
NEW YORK, NY and PETACH TIKVAH, ISRAEL--(Marketwired - Jun 10, 2013) - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has successfully treated the eighth patient in its ongoing Phase IIa ALS clinical trial at the Hadassah Medical Center in Jerusalem, Israel, thus completing treatment of the second of three cohorts. Enrollment of the final group of four patients has also been completed, and the company expects to conclude treatment of these patients by the end of the third quarter of this year.
In this Phase IIa dose-escalating trial, currently underway at Hadassah under the direction of Principal Investigator Professor Dimitrios Karussis, 12 ALS patients are receiving combined intramuscular (IM) and intrathecal (IT) administration of NurOwn cells, in three cohorts, with increasing doses. The study participants will be monitored for six months following transplantation.
About BrainStorm Cell Therapeutics, Inc. BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company's website at http://www.brainstorm-cell.com.
Safe Harbor Statement - Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may," "should," "would," "could," "will," "expect," "likely," "believe," "plan," "estimate," "predict," "potential," and similar terms and phrases are intended to identify these forward-looking statements.The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov.These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements.The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
View post:
BrainStorm Treats 8th Patient in Phase IIa Trial; Completes Enrollment of Final 4 Patients
The Science of Mesenchymal Stem Cells and Regenerative Medicine - Arnold Caplan PhD (Part 1)
Professor Arnold Caplan of Case Western Reserve University is widely regarded as "The Father of the Mesenchymal Stem Cell". This lecture is a "must see" for ...
By: http://www.cellmedicine.com
Go here to see the original:
The Science of Mesenchymal Stem Cells and Regenerative Medicine - Arnold Caplan PhD (Part 1) - Video